These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases. Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016 [TBL] [Abstract][Full Text] [Related]
13. Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis. Noman M; Ferrante M; Bisschops R; De Hertogh G; Van den Broeck K; Rans K; Rutgeerts P; Vermeire S; Van Assche G J Crohns Colitis; 2017 Sep; 11(9):1085-1089. PubMed ID: 28369329 [TBL] [Abstract][Full Text] [Related]
14. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo. Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249 [TBL] [Abstract][Full Text] [Related]
15. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444 [TBL] [Abstract][Full Text] [Related]
16. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Arijs I; De Hertogh G; Lemmens B; Van Lommel L; de Bruyn M; Vanhove W; Cleynen I; Machiels K; Ferrante M; Schuit F; Van Assche G; Rutgeerts P; Vermeire S Gut; 2018 Jan; 67(1):43-52. PubMed ID: 27802155 [TBL] [Abstract][Full Text] [Related]
17. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? D'Amico F; Danese S; Peyrin-Biroulet L Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748 [No Abstract] [Full Text] [Related]
18. Alterations in MAdCAM1-Positive Mucosal Capillaries and Integrin a4b7-Positive Lymphocytes in Crohn's Disease Treated with Anti-TNFα Biologics. Younes M; DuPont AW; Cash BD; Ertan A Ann Clin Lab Sci; 2021 Sep; 51(5):678-685. PubMed ID: 34686510 [TBL] [Abstract][Full Text] [Related]
19. Circulating exosomes express α4β7 integrin and compete with CD4+ T cells for the binding to Vedolizumab. Domenis R; Marino M; Cifù A; Scardino G; Curcio F; Fabris M PLoS One; 2020; 15(11):e0242342. PubMed ID: 33180848 [TBL] [Abstract][Full Text] [Related]
20. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Arihiro S; Ohtani H; Suzuki M; Murata M; Ejima C; Oki M; Kinouchi Y; Fukushima K; Sasaki I; Nakamura S; Matsumoto T; Torii A; Toda G; Nagura H Pathol Int; 2002; 52(5-6):367-74. PubMed ID: 12100519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]